Evropska unija - latvijščina - EMA (European Medicines Agency)

santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - oftalmoloģiskie līdzekļi - samazināt paaugstinātu intraokulāro spiedienu (ias) pieaugušiem pacientiem ar primāra atvērta kakta glaukoma vai acs hipertensijas.

Evropska unija - latvijščina - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinātrija - trombocitopēnija - citi hemostatiskie līdzekļi sistēmiskai lietošanai - tavlesse ir indicēts, lai ārstētu hronisku trombocitopēnija imūnās (ipp) pieaugušiem pacientiem, kam ir grūti kūstoši uz citām zālēm.

Evropska unija - latvijščina - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - osteoporoze - kalcija homeostāze - qutavina is indicated in adults. osteoporozes ārstēšana sievietēm pēc menopauzes un vīriešiem ar paaugstinātu lūzuma risku. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. attieksmi pret osteoporozi saistīts ar ilgstošu sistēmisku glikokortikoīdu terapiju sievietēm, gan vīriešiem, paaugstināts lūzums.

Evropska unija - latvijščina - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipīdu modificējoši aģenti - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Latvija - latvijščina - myHealthbox

bayer ag -

Evropska unija - latvijščina - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - other nervous system drugs - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Evropska unija - latvijščina - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leikēmija, mielogēns, hronisks, bcr-abl pozitīvs - antineoplastiski līdzekļi - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Evropska unija - latvijščina - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemophilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Evropska unija - latvijščina - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Evropska unija - latvijščina - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmoloģiskie līdzekļi - eylea ir norādīts ārstēšanai pieaugušajiem:neovascular (wet) vecuma saistīto makulas deģenerāciju (amd);redzes traucējumiem, jo makulas tūska vidusskolas tīklenes vēnu oklūzija (filiāle rvo vai centrālās rvo);redzes traucējumiem, jo diabētiskā makulas tūska (dme);redzes traucējumiem, jo tuvredzīgs choroidal neovascularisation (tuvredzīgs cnv).